Table 3.
Baseline characteristics of the total study patients.
| Variable | Treatment group (n = 200) | Control group (n = 100) | χ 2/t | P values |
|---|---|---|---|---|
| Age, mean (SD), y | 33.34 (6.86) | 34.01 (8.32) | 0.7415 | 0.4590# |
| Range | 21–59 | 22–63 | ||
| Sex, n (%) | 0.1904 | 0.6625※ | ||
| Male | 137 (68.50) | 66 (66.00) | ||
| Female | 63 (31.50) | 34 (34.00) | ||
| Clinical course, mean (SD), m | 86.35 (72.13) | 90.56 (70.48) | 0.4808 | 0.6310# |
| ALT, mean (SD), U/L | 26.40 (8.71) | 26.57 (7.92) | 0.1640 | 0.8698# |
| HBV DNA, mean (SD), log10 IU/mL | 8.15 (1.13) | 8.17 (1.02) | 0.1479 | 0.8825# |
| HBV DNA baseline level, n (%) | ||||
| 5 to <7 log10 IU/mL | 28 (14.00) | 11 (11.00) | 0.5305 | 0.4664※ |
| 7 to <9 log10 IU/mL | 141 (70.50) | 74 (74.00) | 0.4022 | 0.5260※ |
| >9 log10 IU/mL | 31 (15.50) | 15 (15.00) | 0.0128 | 0.9098※ |
| HBsAg, mean (SD), log10 IU/mL | 4.56 (0.62) | 4.60 (0.60) | 0.5030 | 0.6154# |
SD: standard deviation; ALT: alanine aminotransferase; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen.
※Chi-square test.
# t-test.